Compare ProShares Ultra Silver ETF (AGQ) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares Ultra Silver ETF vs TransMedics Group Inc — how do they compare? ProShares Ultra Silver ETF trades at $80.5, while TransMedics Group Inc trades at $87.08 (market cap $3.10B). The key difference: TransMedics Group Inc is trading nearer its 52-week high, ProShares Ultra Silver ETF nearer its low. Which is the better fit depends on your goals.
| AGQ | TMDX | |
|---|---|---|
Sector | Leveraged / Inverse | Technology |
52-Week High | $400.47 | $150.42 |
52-Week Low | $49.73 | $61.99 |
Market Cap | — | $3.10B |
Enterprise Value | — | $3.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AGQ, the ProShares Ultra Silver ETF, trades at $81.00, down 1.07% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The leveraged ETF structure amplifies silver price moves, with recent volatility highlighted by a 9.39% surge on silver rallies but a 16% crash in June 2026. Financial ratios are not applicable as this is an ETF tracking silver futures.
Outlook hinges on silver price direction, offering amplified gains if silver rallies but severe decay in downturns. Key risks include structural decay from daily leverage resets and silver's sensitivity to Fed policy. Investors must weigh high volatility against silver's bullish momentum.
TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.
The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ProShares Ultra Silver ETF
AGQ is a leveraged ETF that seeks daily investment results corresponding to two times (2x) the daily performance of silver bullion. It is designed for investors seeking magnified short-term exposure to silver prices.
Read more on AGQ →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
